Status In progress
Process STA
ID number 944

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors AbbVie (venetoclax)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Chronic Lymphocytic Leukaemia Support Association
  Leukaemia CARE
  Lymphoma Association
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies Genzyme Europe BV (alemtuzumab) (confidentiality agreement not signed not participating)
  Roche Products (rituximab)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
06 September 2017 Expected publication
14 June 2017 Committee meeting: 3
11 May 2017 - 02 June 2017 Appraisal consultation: 2
16 March 2017 Committee meeting: 2
15 February 2017 - 08 March 2017 Appraisal consultation: 1
18 January 2017 Committee meeting: 1
15 August 2016 Invitation to participate
22 July 2016 Draft scope documents
01 July 2016 Draft scope documents
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance